Researchers examined data from more than 606,000 American veterans with type 2 diabetes. Compared to patients using another common diabetes medication, they discovered that people who began taking a GLP-1 receptor agonist had a 14% lower overall risk of developing a new substance use disorder and up to 25% lower risk for specific conditions involving alcohol, opioids, nicotine, cannabis, or cocaine. GLP-1 users with existing substance use issues also experienced fewer overdoses, hospitalizations, emergency visits, and related deaths.
If you’ve noticed your desire for alcohol or other habits dropping while on semaglutide or tirzepatide for weight loss, you’re not alone.
GLP-1 receptor agonists were originally designed for diabetes and weight loss, but evidence suggests they may also quiet the brain’s reward pathways involved in addiction.
In this guide, we’ll explore the science behind GLP-1 medications and addiction, what current research says, and whether these treatments may offer benefits beyond weight loss.
What Are GLP-1 Medications?
GLP-1 medications, also known as GLP-1 receptor agonists, are a class of injectable and, more recently, oral drugs that mimic a natural hormone your body releases after eating. Originally developed to treat type 2 diabetes, GLP-1s have become helpful in supporting weight loss by reducing hunger, slowing digestion, and improving insulin response.
Some of the GLP-1 medications prescribed today include:
- Semaglutide: the active ingredient in Ozempic, used to treat diabetes, and Wegovy (oral and injection), used for weight loss.
- Tirzepatide: The active ingredient in Mounjaro for diabetes and Zepbound for weight loss. Tirzepatide also targets GIP receptors for even stronger effects.
- Liraglutide: found in Victoza and Saxenda
GLP-1s may help regulate blood sugar by stimulating insulin release when glucose levels are high and by reducing glucose production by the liver. They also act on the brain’s hunger centers, helping you feel full faster and for longer periods after eating.
These medications also slow digestion by delaying stomach emptying, further promoting a lasting sense of fullness. Additionally, GLP-1 medications may help reduce cravings for certain foods and other substances by influencing brain pathways involved in reward and impulse control.
What Is Addiction?
Addiction is a lack of control over doing, consuming, or using anything to the point where it could be dangerous to you.
Addiction is most frequently linked to gambling, drugs, alcohol, and smoking, but it’s possible to be addicted to anything.
Drugs like alcohol, opioids, and nicotine impact your mental and physical well-being. These feelings might be pleasurable and result in a strong desire to use the drugs one more time.
After winning, gambling can produce a similar mental “high” that is followed by a strong desire to try again and experience the same feeling. This may become a habit very difficult to break.
The Link Between GLP-1 Medications and Addiction
GLP-1 receptors are not only found in the gut, but they also play a role in the brain’s reward pathway by influencing the release of dopamine, a key chemical involved in motivation and reward. These receptors are present in brain regions responsible for decision-making, impulse control, and pleasure-seeking behaviors.
Dopamine is a neurotransmitter, or chemical signaling messenger, that plays a central role in addiction. Activities such as consuming drugs, drinking alcohol, or even engaging in pleasurable behaviors can temporarily increase dopamine levels above normal. Over time, this reinforces repeated behaviors, making the brain’s reward system a key target for addiction treatment.
GLP-1 medications may help “dial down” the brain’s response to these rewarding stimuli, including highly palatable foods, alcohol, nicotine, and other substances that can trigger addictive patterns. They appear to reduce dopamine spikes associated with reward-driven behaviors, helping to regulate the brain’s response.
Rather than blocking pleasure entirely, these medications may help normalize how the brain processes reward, making cravings less intense and easier to manage.
Can GLP-1 Medications Help With Specific Addictions?
While GLP-1 medications are not currently approved to treat addiction, increasing studies and user experiences show that GLP-1 drugs may affect some craving-driven behaviors. These medications may reduce the intensity of cravings associated with foods and substances by influencing appetite, reward systems, and impulse control. Here’s how they may affect specific types of addiction:
GLP-1s and food addiction
While food addiction is not yet formally recognized as a psychiatric condition in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), experts acknowledge that people can develop addictive-like behaviors around food, especially highly processed foods rich in sugar, salt, fat, and artificial flavorings, which can lead to compulsive overeating.
GLP-1 medications are primarily approved for treating type 2 diabetes and supporting weight management in people with obesity, but they are also showing promise in helping with food-related cravings. Many people have reported that these medications have helped quiet “food noise,” which is the persistent thoughts and cravings about food.
This is likely tied to how GLP-1 medications influence the brain’s reward system, particularly by regulating dopamine, which plays a role in reinforcing cravings and habitual behaviors.
While cravings can return once you stop GLP-1, you can maintain progress with lifestyle changes such as balanced nutrition, regular physical activity, and behavioral support.
GLP-1s and alcohol cravings
According to a recent study of U.S. veterans with type 2 diabetes, GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide were associated with a significant reduction in alcohol-related issues.
Users had an 18% lower risk of developing a new alcohol use disorder. Among those with existing alcohol issues, the same medications were linked to 31% fewer emergency visits, 26% fewer hospitalizations, and 50% lower substance-related mortality.
A separate 2025 study tested once-weekly low-dose semaglutide in adults with alcohol use disorder (AUD). Participants receiving semaglutide drank fewer drinks per drinking day, reported lower weekly cravings, and showed greater reductions in heavy drinking days compared with placebo. Many people described the “pull” toward alcohol fading.
GLP-1s and opioid use disorder
The above analysis found a 25% lower risk of new opioid use disorder and a 39% lower risk of overdose among those already diagnosed. Other observational studies have resonated with this, showing fewer opioid-related events in people prescribed GLP-1 medications for diabetes or weight loss.
GLP-1s and nicotine, and tobacco use
GLP-1 therapy was associated with a 20% lower risk of nicotine use disorder (NUD). Other studies have shown a reduction in cravings for cigarettes in people using GLP-1s, with reports suggesting that up to 17% of surveyed participants became ex-smokers after starting GLP-1 therapy.
Researchers are also exploring whether these medications can benefit those with addictions to gambling and sex, among other things.
Risks and Side Effects
While GLP-1s may prove effective, like any medication, they have side effects that can vary by individual.
Most common side effects
These usually occur in the first few weeks and often improve as your body adjusts:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Dizziness
- Stomach pain
- bloating
- Decreased appetite
- Mild fatigue
- headache
- Injection-site reactions
Serious but rare risks
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems (stones or inflammation)
- Low blood sugar
- Thyroid tumors
It’s important to note that GLP-1 medications are not yet FDA-approved as a standalone treatment for alcohol, opioid, or nicotine addiction. They are prescribed off-label and work best as an add-on to counseling, support groups, or established addiction programs, not a replacement.
If you have a history of pancreatitis, gallbladder disease, thyroid cancer, or severe gastrointestinal issues, you may not be eligible for GLP-1 therapy. Our team will review your full medical history, current medications, and goals during a virtual or in-person consult to determine your eligibility.
Should You Use GLP-1 Medications for Addiction?
GLP-1 medications show real promise for reducing cravings and substance use, but they are not a standalone cure for addiction. They work best as an add-on tool for the right people and only under the guidance of an experienced provider.
Consider GLP-1 therapy if:
- You already qualify for GLP-1s because of obesity, type 2 diabetes, or metabolic syndrome.
- You’ve noticed your cravings dropping while taking semaglutide or tirzepatide for weight loss.
- You’re already in counseling, AA/NA, or working with an addiction specialist and want extra support for cravings.
Avoid GLP-1 if:
- Addiction is your only medical issue, and you don’t meet criteria for weight loss or diabetes treatment.
- You need immediate, intensive addiction care.
- You have GLP-1 contraindications (thyroid cancer history, pancreatitis).
- You’re hoping for a “magic shot” without combining it with therapy or support groups.
FAQs About GLP-1s and Addictions
Can Ozempic treat addiction?
Ozempic is not FDA-approved to treat addiction. However, studies have shown that GLP-1 users have a 14–25% lower risk of new substance use disorders and fewer related hospitalizations. Many people notice reduced cravings as a side effect while using it for weight loss or diabetes.
Does semaglutide reduce alcohol cravings?
Early evidence suggests it can. A randomized trial showed that once-weekly semaglutide lowered drinks per drinking day and reduced alcohol cravings compared with a placebo.
Are GLP-1s FDA-approved for substance use disorders?
GLP-1 medications are currently FDA-approved only for type 2 diabetes and chronic weight management. They are not approved for substance use disorders.
How long does it take to notice reduced cravings?
Most people report noticing reduced cravings for substance use or food within 2–4 weeks once they reach a stable dose. Some feel changes as early as the first 1–2 weeks during dose titration. Some studies showed measurable drops in alcohol cravings by week 4.
Get Started with GLP-1 Medications
Studies show that GLP-1 medications like semaglutide and tirzepatide are not only helping people lose weight, but they’re also calming the brain’s reward pathways and reducing cravings for substance use. While these medications are not a cure for addiction, they work when used alongside counseling, support groups, and personalized medical care.
At NP2GO, we are always focused on the overall well-being of our patients and the communities we serve. If you would like more information about our services, please explore our website. Feel free to call 405-696-7003 with specific questions and concerns. We would love to hear from you.
Whether you prefer the convenience of a virtual visit available in 38 states plus Washington, D.C., or an in-person appointment in Oklahoma, we make the process simple and supportive.
Book your virtual or in-office consult with us today to learn more about GLP-1 therapy and our services.